Discovery of a Novel Cabazitaxel Nanoparticle–Drug Conjugate (CRLX522) with Improved Pharmacokinetic Properties and Anticancer Effects Using a β-Cyclodextrin–PEG Copolymer Based Delivery Platform
Author:
Affiliation:
1. Novartis Institutes for BioMedical Research Inc., 181 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States
2. Cerulean Pharma Inc., 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States
Funder
Novartis
Publisher
American Chemical Society (ACS)
Subject
Drug Discovery,Molecular Medicine
Link
https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.9b00892
Reference68 articles.
1. Cancer nanomedicine: progress, challenges and opportunities
2. Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology
3. Spatial–temporal event adaptive characteristics of nanocarrier drug delivery in cancer therapy
4. Macromolecular therapeutics in cancer treatment: The EPR effect and beyond
5. Stimuli-responsive nanocarriers for drug delivery
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Influence of unsaturated fatty acids on the antitumor activity of polymeric conjugates grafted with cabazitaxel against prostate cancer;Biomedicine & Pharmacotherapy;2023-12
2. Cyclodextrin in drug delivery;Natural Biopolymers in Drug Delivery and Tissue Engineering;2023
3. Acid-sensitive PEGylated cabazitaxel prodrugs for antitumor therapy;Chinese Chemical Letters;2021-05
4. Recent progress in nanoformulations of cabazitaxel;Biomedical Materials;2021-03-03
5. Novel multi-stimuli responsive functionalized PEG-based co-delivery nanovehicles toward sustainable treatments of multidrug resistant tumor;Journal of Materials Chemistry B;2021
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3